LOGIX in Medical Technology
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
BOSTON, Jan. 8 /PRNewswire/ -- Surface Logix
today announced positive
results in the Company's Phase 2a clinical trial of SLx-2101 in
hypertension. The randomized, double-blind, placebo-controlled crossover
Phase 2a study in 60 patients with uncontrolled hypertension demonstrated
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
BOSTON, Oct. 5 /PRNewswire/ -- Surface Logix, Inc. today announced the
presentation of positive safety and efficacy data from its innovative Phase
1 repeat-dose clinical trial of its investigational drug candidate
SLx-4090, a first-in-class enterocyte-specific microsomal triglyceride
Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
...n will take place
on Wednesday, November 28, 2007 at 2:50 PM EST.
currently has two programs in human clinical trials with
a third program in...www.surfacelogix.com .
Contact: Leland Webster, Ph.D., M.B.A. Surface logix
Inc. Vice President, Corporate Development 617.746.8520
Media: Sarah C...
LOGIX in Biological Technology
Surface Logix Appoints Keith Dionne as President and Chief Executive Officer
BOSTON, Oct. 14 /PRNewswire/ -- Surface Logix, a privately held
biopharmaceutical company focused on using biophysical chemistry to create
and develop novel small molecule drugs, is pleased to announce the
appointment of Keith Dionne, Ph.D. to the position of President and Chief
Surface Logix Announces Executive Management Changes
BOSTON, May 15 /PRNewswire/ -- Surface Logix
today announced that Jim
Mahoney, President & CEO, will be stepping down from his current position
to pursue other interests. Mr. Mahoney will maintain a consulting
relationship with the company for the foreseeable future. Steven Gillis,
Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
BOSTON, Jan. 29 /PRNewswire/ -- Surface Logix
today announced positive
results in the Company's Phase 2a clinical trial of SLx-4090 in
dyslipidemia (high cholesterol and triglyceride levels in the bloodstream).
The randomized, double-blind, placebo-controlled Phase 2a study in 24
NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
... of Dobson Communications, sitting on both the
Audit and Compensation Committees, through the 2007 sale of Dobson to AT&T.
He was President and CEO of logix
Communications, a Competitive Local
Exchange Carrier operating primarily in Texas and Oklahoma, from 1999
through 2001. Following that he spent two ye...
LOGIX in Biological Products
APO LOGIX - JC-1 Mitochondrial Membrane Potential Detection Kit from BACHEM
Description: In situ detection of apoptosis and mitochondrial membrane potential. The mitochondrial permeability transition event provides an early indication of the initiation of cellular apoptosis. This process is typically defined as a collapse in the electrochemical gradient across the mitochondrial membran...